Overall rank by patents
#42,315
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Pulmokine, Inc.
USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, active 2017–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
6
Total patents granted
4
CPC technology areas
16.2
Avg claims per patent
-50%
5-year filing velocity
The verdict
Pulmokine holds 6 US patents across 4 technology areas, rank #42,315 of 50,000 tracked assignees.
- #42,315
- of 50,000 US assignees by volume
- Top 82%
- by Innovation Score (25.7/100)
- 16.2
- avg claims per patent
- -50%
- filing velocity, last 5 yrs
Portfolio overview
Pulmokine, Inc. has been granted 6 US utility patents between 2017 and 2022, placing Pulmokine, Inc. at rank #42,315 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Pulmokine, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Pulmokine sits between PTO Genius, Llc (6 patents, rank #42,311) and Purus Power Corporation (6 patents, rank #42,319) - the closest US assignees by grant volume. The composite Innovation Score of 25.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 4 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Pulmokine, Inc.'s 16.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Pulmokine, Inc. against peers pursuing similar technology classes.
Who files at Pulmokine's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- PTO Genius
PTO GENIUS, LLC
6 patents
- Pubwise LLLP
PUBWISE, LLLP
6 patents
- Pucline
PUCLINE, LLC
6 patents
- PUKU
PUKU LIMITED
6 patents
- Pulsenmore
PULSENMORE LTD
6 patents
- PURE Lithium
PURE LITHIUM CORPORATION
6 patents
- Puritan Medical P…
PURITAN MEDICAL PRODUCTS COMPANY, LLC
6 patents
- Purus Power
PURUS POWER CORPORATION
6 patents
- Pulmokine ◀
PULMOKINE, INC.
6 patents
What this shows Pulmokine holds 6 patents at rank #42,315, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Pulmokine
By rank, the assignees closest to #42,315 in granted patent volume.
- PTO Genius, Llc #42,311 · 6 patents
- Pubwise, LLLP #42,312 · 6 patents
- Pucline, Llc #42,313 · 6 patents
- PUKU Limited #42,314 · 6 patents
- Pulsenmore Ltd #42,316 · 6 patents
- PURE Lithium Corporation #42,317 · 6 patents
- Puritan Medical Products Company, Llc #42,318 · 6 patents
- Purus Power Corporation #42,319 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Pulmokine's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Pulmokine's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
26 Top 82% higher than 18% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2019 | 2 | 33.3% |
| 2020 | 1 | 16.7% |
| 2022 | 1 | 16.7% |
Which technologies does Pulmokine, Inc. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Pulmokine, Inc. hold?
Pulmokine, Inc. holds 6 US granted patents filed between 2017 and 2022, spanning 4 technology areas.
What is Pulmokine, Inc.'s Innovation Score?
Pulmokine, Inc. has an Innovation Score of 25.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Pulmokine, Inc. focus on?
Pulmokine, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 4 CPC subclasses total.
Is Pulmokine, Inc.'s patent filing rate increasing or decreasing?
Pulmokine, Inc.'s recent filing velocity is -50% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Pulmokine, Inc.'s patents?
Pulmokine, Inc.'s patents average 16.2 claims each. This falls within the standard range, providing solid legal coverage.
How is the Pulmokine, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Pulmokine's 6 grants land it in the top 82% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Pulmokine ranks #42,315 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.